Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × pyrotinib × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 9 HER2-positive Breast Cancer 4 Salivary Gland Neoplasms 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2 Positive Breast Cancer 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Invasive 1 Breast Cancer Female 1 Advanced Digestive System Tumor 1 Advanced Breast Cancer 1

Interventions

pembrolizumab 38 Gemcitabine 20 enfortumab vedotin 19 Cisplatin 17 Nivolumab 16 atezolizumab 14 Magnetic Resonance Spectroscopy 14 avelumab 13 Carboplatin 12 Specimen Handling 10 Docetaxel 10 sacituzumab govitecan 9 Paclitaxel 7 Ipilimumab 7 Fluorodeoxyglucose F18 5 pemigatinib 4 toripalimab 3 erdafitinib 3 durvalumab 3 cabozantinib 3 X-Rays 3 Taxes 3 Mitomycin 3 Immunoglobulin G 3 CTLA-4 Antigen 3 Biopsy 3 tislelizumab 2 lenvatinib 2 eribulin 2 dodecyl maltoside 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡